We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA.
We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and clinical data discovered.
Details of the abstract and poster presentation are as follow:
Poster #82769
Abstract #00362
Theme: Clinical Trials: Biomarkers including plasma
Presentation Title: Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins
Information about CTAD 2023 can be found at https://www.ctad-alzheimer.com/